OD’s Kramer Retires After 31 Years
Dr. Barnett “Barry” Kramer, director of the Office of Disease Prevention within
OD, retired from federal service Dec. 3 after 31 years in the government, 24 of which were spent at NIH.
Kramer, who spent many years working at the National Cancer Institute in a variety of positions
including deputy director of NCI’s Division
of Cancer Prevention and Control (now the Division of Cancer Prevention), is also editor-in-chief of the Journal of the National Cancer Institute,
a post he has held since 1994 and in which he will continue. The journal is owned by Oxford University Press and is not connected with the federal government.
Board-certified in internal medicine and medical
oncology, Kramer began his career with NCI in 1975 as a clinical associate in the Pediatric
Oncology Branch after earning his medical degree from the University of Maryland Medical
School and completing an internship and residency in internal medicine at Barnes Hospital
in St. Louis. After 8 years on the faculty of the University of Florida College of Medicine in Gainesville, he returned to NIH.
Upon his return, he began work as a senior investigator at NCI’s Navy Medical Oncology Branch and then moved to the NCI Division of Cancer Prevention and Control, first as associate director and then as deputy director. In 2000, he was selected as director of the Office of Medical Applications of Research and, since 2001, he also served as NIH associate director for disease prevention and director of the Office of Disease Prevention.
In 1986, Kramer also became an associate professor
and subsequently a full professor in the department of medicine at the Uniformed Services
University of the Health Sciences. For nearly 20 years, he has also been editor-in-chief of the screening and prevention editorial board of NCI’s Physicians Data Query (PDQ), a comprehensive cancer database. He also is a longstanding member of the PDQ adult treatment editorial board.
During his years at NIH, he received a Meritorious Executive Award, an NIH Merit Award, two NIH Director’s Awards, an HHS Secretary’s Award for Distinguished
Service and has given both a Daniel Ihde Memorial (NCI) Lecture and an NIH Great Teachers Lecture.
Kramer also holds a master’s degree in public health from Johns Hopkins University’s
Bloomberg School of Public Health.
In addition to continuing his work with JNCI during retirement, Kramer will do contract work for NCI’s Office of Communications and Education.—
NIAID’s Nadler Mourned
Dr. Jeffrey P. Nadler, who was deputy director and then acting director of the Therapeutics Research Program in NIAID’s Division of AIDS from 2006 until July 2010, died in hospice care on Nov. 26 at his home in St. Petersburg, Fla. He was 60 years old.
Nadler came to NIH from the University
of South Florida College of Medicine,
where he served for 19 years, most recently as a professor of medicine and public health and director of research in the division of infectious disease. During his tenure there, he oversaw clinical trials
that helped lead to the development of more than 20 antiretroviral drugs for the treatment of HIV infection.
Internationally renowned for his expertise
in HIV/AIDS clinical care, Nadler advised U.S. professional societies, the Food and Drug Administration and the governments of India and Brazil on the development of national clinical guidelines
for HIV care and practice. He also led groups of fellows to clinics in India and Brazil to deliver care to people with HIV/AIDS.
“He believed that everyone deserves the right to a full life,” said Dr. Carl Dieffenbach,
director of DAIDS. “It doesn’t matter whether you’re living in India or Brazil
or Florida or New York. His philosophy was to make sure that the people he interacted with got the best care available and access to medications that would sustain their lives.”
While at NIAID, Nadler worked with the President’s Emergency Plan for AIDS Relief program to help it implement treatment of HIV/AIDS in the developing world. He also helped NIAID begin to formulate a new agenda for improving the treatment of tuberculosis in people who are co-infected with HIV and TB.
“He was a very optimistic person,” said Dr. Mike Ussery, chief of the Drug Development
and Clinical Science Branch, DAIDS. “He was an inspiration to all of us here in the division.”
Nadler suffered from spinocerebellar ataxia, an inherited disease that causes wasting of the spinal cord and cerebellum.
He is survived by his wife, Constance Price; his brother, Gary Nadler, his sister, Debra Battino; and his son, Sandro Humann.—
|Two Digestive Disease Experts Join NIDDK
Dr. Averell H. Sherker recently joined NIDDK’s Liver Disease Research Branch in the Division of Digestive Diseases
as scientific advisor for viral hepatitis and liver
diseases. He will provide scientific
oversight for liver-related research grants and NIDDK-funded clinical research networks. He previously directed the Center for Liver Diseases at Washington Hospital
Center and hepatology research at McGill University. In addition, he was attending physician
in the Liver Transplantation Program at Georgetown University Hospital and continues
as associate professor of clinical medicine at Georgetown University School of Medicine. Sherker received his M.D. from Queen’s University
in Kingston, Ontario, and trained in medicine, gastroenterology and hepatology at the University of Toronto and in molecular virology at Stanford University and Chiba University
in Japan. He coauthored the book Living
With Hepatitis C.
Dr. Michael Grey is the new director of the gastrointestinal
transport and absorption program
in NIDDK’s Division of Digestive
Diseases and Nutrition. He is managing grants aimed at advancing
research on nutrient digestion,
absorption and transport in the gastrointestinal tract, as well as the development,
structure and function of the intestinal tract in health and disease. Grey was a health science
policy analyst in NIDDK’s Office of Scientific Program and Policy Analysis. He graduated with honors from Hofstra University where he studied biochemistry and earned a Ph.D. in biochemistry and molecular biophysics from Columbia University.
He completed postdoctoral research at Harvard
Medical School, where he studied how proteins
on the surface of cells transmit molecular signals across the cell membrane.
|Tosten Named CSR Executive Officer
Timothy J. Tosten is the new executive officer
at the Center for Scientific Review. He will oversee staff and contractors who provide
administrative, financial management, committee management,
information technology, procurement
and management analysis services.
Each year, CSR receives about 80,000 grant applications, uses more than 17,000 reviewers and hosts more than 1,700 review meetings, which require over 60,000 hotel rooms and travel reimbursements.
“Tim rapidly rose to the top of the candidates to take on this critical job,” said CSR director
Dr. Toni Scarpa. “He brings to CSR dynamic
and proven management skills and a strong commitment to service.” He said Tosten has “excelled in progressive leadership positions at NIH since he entered the Presidential Management
Intern program in 1993.”
Tosten comes to CSR from the Fogarty International
Center, where he was executive officer.
He earlier served as associate director for administration for the Division of Intramural Research Programs at the National Institute of Mental Health.
He began his NIH career as a PMI in the Office of Research Services, where he spent 12 years working in various areas including managing
the child care programs and food service contracts, the NIH travel contract and NIH’s first-ever sign language interpreting services contract. He completed his tenure at ORS as director of the Division of Employee Services.
Tosten holds a master of public administration degree from the University of Baltimore.
|Two Named to NIEHS Leadership
NIEHS/NTP director Dr. Linda Birnbaum recently filled two key positions on her leadership
team with the appointments of Dr. Gwen Collman as director of the Division of Extramural
Research and Training (DERT) and Dr. Richard
Woychik as the institute’s deputy director.
Dr. Gwen Collman leads a division that is organized into seven branches and centers, composed of 60 employees, awarding approximately 874 research grants each year for a total of approximately $388 million. In the scientific world, Dr. Richard Woychik has achieved renown for using molecular genetics to identify and study genes involved in a variety of human disorders.
“Dr. Collman and Dr. Woychik bring a wealth of scientific expertise and administrative experience
to these important leadership positions of the NIEHS,” Birnbaum said. “I have every confidence
in their ability to do an extraordinary job in forwarding the scientific interests of the institute.”
Collman plans to build on her career at NIEHS where she began as an epidemiologist in the institute’s Epidemiology Branch following completion
of her doctorate in environmental epidemiology
at the University of North Carolina at Chapel Hill School of Public Health in 1984. In 1992, she moved to DERT as a scientific program
In 2003, Collman became chief of DERT’s Susceptibility
and Population Health Branch, a post she held until being named acting director of the division in 2008.
Woychik was most recently president and chief executive officer of the Jackson Laboratory, headquartered in Bar Harbor, Me., with more than 1,400 employees. Previously, he served as scientific officer for Lynx Therapeutics, head of the Parke-Davis laboratory of molecular genetics
and professor within the departments of pediatrics, genetics and pharmacology at Case Western Reserve University. Woychik worked his way up through the ranks over the course of 10 years to become head of the mammalian
genetics section in the biology division and then director of the Office of Functional Genomics at Oak Ridge National Laboratory.
A leading mammalian geneticist with more than 80 publications and many honors to his credit, Woychik earned his Ph.D. in molecular biology at Case Western. During his 9-year tenure
at the Jackson Laboratory, the institution grew significantly and its total operating budget almost doubled.